Arvinas logo

Potent and Orally Bioavailable BCL6 PROTAC® Degraders Demonstrate Efficacy in Pre-Clinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Sheryl M. Gough, et al.

December 12, 2021
American Society of Hematology (ASH)
Skip to content